Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: swig who wrote (286)	4/5/2000 5:36:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

This is unusual language for a Tgen press release: ``These data suggest that we are moving closer to attaining the holy grail of gene therapy* -- a systemic delivery system,'* said Dr. Barrie J. Carter, Executive Vice President and Director of Research and Development at Targeted Genetics. ``Our ability to deliver genes systemically will expand the number of diseases that may be treatable with gene therapy approaches. We are very excited about the progress we are making in developing a variety of synthetic gene delivery systems, including formulations for systemic and local delivery.' biz.yahoo.com I'd link to the PR from the Targen website, but I cannot open those files. Must have something to do with the fact that MS Word is not my word processor. Any Tgen lurkers? Fix that. There are still a few of us who have not moved to MS office.